The pharmaceutical industry once again reigned supreme on the transactional front this week with Alexion Pharmaceuticals Inc.’s $8.4 billion buy of Synageva BioPharma Corp. The Cheshire, Connecticut-based acquirer specializes in rare disease medication, as does the Lexington, Massachusetts-based target.
Alexion will gain Synageva’s product Kanuma—currently under priority review by the U.S. Food and Drug Administration—through the deal, announced Wednesday. Kanuma has been developed for the treatment of Lysosomal Acid Lipase Deficiency, a potentially fatal condition that causes fatty buildup in the liver and blood vessel walls, according to Synageva.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]